Inflammatory remodeling of the HDL proteome impairs cholesterol efflux capacity

Journal of Lipid Research

Volumn 56, Issue 8, 2015, Pages 1519-1530

  Vaisar, Tomáš ^a   Tang, Chongren ^a   Babenko, Ilona ^a   Hutchins, Patrick ^a   Wimberger, Jake ^a   Suffredini, Anthony F ^b   Heinecke, Jay W ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Apolipoproteins; Atherosclerosis; High density lipoprotein; Inflammation; Mass spectrometry; Proteomics

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROTEOME; SERUM AMYLOID A; ENDOTOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; INFLAMMATION; LIPID ANALYSIS; LIPID COMPOSITION; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; ADULT; ANIMAL; BLOOD; CARDIAC MUSCLE; CELL PROTECTION; CHEMISTRY; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; HUMAN; MACROPHAGE; MALE; METABOLISM;

ADULT; ANIMALS; CHOLESTEROL, HDL; CYTOPROTECTION; ENDOTOXINS; HUMANS; INFLAMMATION; MACROPHAGES; MALE; MICE; MYOCARDIUM; PROTEOME; SERUM AMYLOID A PROTEIN;

EID: 84941308579     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M059089     Document Type: Article

References (80)

1. Wilson, P. W., R. B. D'Agostino, D. Levy, A. M. Belanger, H. Silbershatz, and W. B. Kannel. 1998. Prediction of coronary heart disease using risk factor categories. Circulation. 97: 1837-1847.
2. Tall, A. R., L. Yvan-Charvet, N. Terasaka, T. Pagler, and N. Wang. 2008. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab. 7: 365-375.
3. Rader, D. J., and A. R. Tall. 2012. The not-so-simple HDL story: is it time to revise the HDL cholesterol hypothesis? Nat. Med. 18: 1344-1346.
4. Heinecke, J. W. 2012. The not-so-simple HDL story: a new era for quantifying HDL and cardiovascular risk? Nat. Med. 18: 1346-1347.
5. Rader, D. J., and G. K. Hovingh. 2014. HDL and cardiovascular disease. Lancet. 384: 618-625.
6. Francis, G. A. 2010. The complexity of HDL. Biochim. Biophys. Acta. 1801: 1286-1293.
7. Rosenson, R. S., H. B. Brewer, W. S. Davidson, Z. A. Fayad, V. Fuster, J. Goldstein, M. Hellerstein, X-C. Jiang, M. C. Phillips, D. J. Rader, et al. 2012. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 125: 1905-1919.
8. de la Llera-Moya, M., D. Drazul-Schrader, B. F. Asztalos, M. Cuchel, D. J. Rader, and G. H. Rothblat. 2010. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler. Thromb. Vasc. Biol. 30: 796-801.
9. Khera, A. V., M. Cuchel, M. de la Llera-Moya, A. Rodrigues, M. F. Burke, K. Jafri, B. C. French, J. A. Phillips, M. L. Mucksavage, R. L. Wilensky, et al. 2011. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364: 127-135.
10. Shao, B., C. Tang, A. Sinha, P. S. Mayer, G. D. Davenport, N. Brot, M. N. Oda, X. Q. Zhao, and J. W. Heinecke. 2014. Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase. Circ. Res. 114: 1733-1742.
11. Li, X. M., W. H. Tang, M. K. Mosior, Y. Huang, Y. Wu, W. Matter, V. Gao, D. Schmitt, J. A. Didonato, E. A. Fisher, et al. 2013. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler. Thromb. Vasc. Biol. 33: 1696-1705.
12. Rohatgi, A., A. Khera, J. D. Berry, E. G. Givens, C. R. Ayers, K. E. Wedin, I. J. Neeland, I. S. Yuhanna, D. R. Rader, J. A. de Lemos, et al. 2014. HDL cholesterol efflux capacity and incident cardiovascular events. N. Engl. J. Med. 371: 2383-2393.
13. Lewis, G. F., and D. J. Rader. 2005. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. 96: 1221-1232.
14. Van Lenten, B. J., S. Y. Hama, F. C. de Beer, D. M. Stafforini, T. M. McIntyre, S. M. Prescott, B. N. La Du, A. M. Fogelman, and M. Navab. 1995. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 96: 2758-2767.
15. Barter, P. J., S. Nicholls, K. A. Rye, G. M. Anantharamaiah, M. Navab, and A. M. Fogelman. 2004. Antiinflammatory properties of HDL. Circ. Res. 95: 764-772.
16. Vaisar, T., B. Shao, P. S. Green, M. N. Oda, J. F. Oram, and J. W. Heinecke. 2007. Myeloperoxidase and inflammatory proteins: pathways for generating dysfunctional high-density lipoprotein in humans. Curr. Atheroscler. Rep. 9: 417-424.
17. Feingold, K. R., and C. Grunfeld. 2010. The acute phase response inhibits reverse cholesterol transport. J. Lipid Res. 51: 682-684.
18. Sorci-Thomas, M. G., and M. J. Thomas. 2012. High density lipoprotein biogenesis, cholesterol efflux, and immune cell function. Arterioscler. Thromb. Vasc. Biol. 32: 2561-2565.
19. van der Westhuyzen, D. R., F. C. de Beer, and N. R. Webb. 2007. HDL cholesterol transport during inflammation. Curr. Opin. Lipidol. 18: 147-151.
20. Banka, C. L., T. Yuan, M. C. de Beer, M. Kindy, L. K. Curtiss, and F. C. de Beer. 1995. Serum amyloid A (SAA): influence on HDLmediated cellular cholesterol efflux. J. Lipid Res. 36: 1058-1065.
21. McGillicuddy, F. C., M. de la Llera Moya, C. C. Hinkle, M. R. Joshi, E. H. Chiquoine, J. T. Billheimer, G. H. Rothblat, and M. P. Reilly. 2009. Inflammation impairs reverse cholesterol transport in vivo. Circulation. 119: 1135-1145.
22. Annema, W., N. Nijstad, M. Tolle, J. F. de Boer, R. V. Buijs, P. Heeringa, M. van der Giet, and U. J. Tietge. 2010. Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A(2). J. Lipid Res. 51: 743-754.
23. Artl, A., G. Marsche, S. Lestavel, W. Sattler, and E. Malle. 2000. Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler. Thromb. Vasc. Biol. 20: 763-772.
24. Navab, M., S. Hama-Levy, B. J. Van Lenten, G. C. Fonarow, C. J. Cardinez, L. W. Castellani, M. L. Brennan, A. J. Lusis, A. M. Fogelman, and B. N. La Du. 1997. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J. Clin. Invest. 99: 2005-2019.
25. Getz, G. S., and C. A. Reardon. 2004. Paraoxonase, a cardioprotective enzyme: continuing issues. Curr. Opin. Lipidol. 15: 261-267.
26. Davidson, W. S., R. A. Silva, S. Chantepie, W. R. Lagor, M. J. Chapman, and A. Kontush. 2009. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler. Thromb. Vasc. Biol. 29: 870-876.
27. Tchoua, U., C. Rosales, D. Tang, B. K. Gillard, A. Vaughan, H. Y. Lin, H. S. Courtney, and H. J. Pownall. 2010. Serum opacity factor enhances HDL-mediated cholesterol efflux, esterification and antiinflammatory effects. Lipids. 45: 1117-1126.
28. Suffredini, A. F., H. D. Hochstein, and F. G. McMahon. 1999. Doserelated inflammatory effects of intravenous endotoxin in humans: evaluation of a new clinical lot of Escherichia coli O:113 endotoxin. J. Infect. Dis. 179: 1278-1282.
29. de Beer, M. C., N. R. Webb, J. M. Wroblewski, V. P. Noffsinger, D. L. Rateri, A. Ji, D. R. van der Westhuyzen, and F. C. de Beer. 2010. Impact of serum amyloid A on high density lipoprotein composition and levels. J. Lipid Res. 51: 3117-3125.
30. Kisilevsky, R., M. D. Benson, M. A. Axelrad, and L. Boudreau. 1979. The effect of a liver protein synthesis inhibitor on plasma SAA levels in a model of accelerated amyloid deposition. Lab. Invest. 41: 206-210.
31. Sipe, J. D., I. Carreras, W. A. Gonnerman, E. S. Cathcart, M. C. de Beer, and F. C. de Beer. 1993. Characterization of the inbred CE/J mouse strain as amyloid resistant. Am. J. Pathol. 143: 1480-1485.
32. Coetzee, G. A., A. F. Strachan, D. R. van der Westhuyzen, H. C. Hoppe, M. S. Jeenah, and F. C. de Beer. 1986. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J. Biol. Chem. 261: 9644-9651.
33. Vaisar, T., S. Pennathur, P. S. Green, S. A. Gharib, A. N. Hoofnagle, M. C. Cheung, J. Byun, S. Vuletic, S. Kassim, P. Singh, et al. 2007. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 117: 746-756.
34. Green, P. S., T. Vaisar, S. Pennathur, J. J. Kulstad, A. B. Moore, S. Marcovina, J. Brunzell, R. H. Knopp, X-Q. Zhao, and J. W. Heinecke. 2008. Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation. 118: 1259-1267.
35. Cabana, V. G., N. Feng, C. A. Reardon, J. Lukens, N. R. Webb, F. C. de Beer, and G. S. Getz. 2004. Influence of apoA-I and apoE on the formation of serum amyloid A-containing lipoproteins in vivo and in vitro. J. Lipid Res. 45: 317-325.
36. Jahangiri, A., M. C. de Beer, V. Noffsinger, L. R. Tannock, C. Ramaiah, N. R. Webb, D. R. van der Westhuyzen, and F. C. de Beer. 2009. HDL remodeling during the acute phase response. Arterioscler. Thromb. Vasc. Biol. 29: 261-267.
37. Tang, C., Y. Liu, P. S. Kessler, A. M. Vaughan, and J. F. Oram. 2009. The macrophage cholesterol exporter ABCA1 functions as an antiinflammatory receptor. J. Biol. Chem. 284: 32336-32343.
38. Egertson, J. D., A. Kuehn, G. E. Merrihew, N. W. Bateman, B. X. MacLean, Y. S. Ting, J. D. Canterbury, D. M. Marsh, M. Kellmann, V. Zabrouskov, et al. 2013. Multiplexed MS/MS for improved dataindependent acquisition. Nat. Methods. 10: 744-746.
39. MacLean, B., D. M. Tomazela, N. Shulman, M. Chambers, G. L. Finney, B. Frewen, R. Kern, D. L. Tabb, D. C. Liebler, and M. J. MacCoss. 2010. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics. 26: 966-968.
40. Hoofnagle, A. N., J. O. Becker, M. N. Oda, G. Cavigiolio, P. Mayer, and T. Vaisar. 2012. Multiple-reaction monitoring-mass spectrometric assays can accurately measure the relative protein abundance in complex mixtures. Clin. Chem. 58: 777-781.
41. Liu, H., R. G. Sadygov, and J. R. Yates III. 2004. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal. Chem. 76: 4193-4201.
42. Becker, L., S. A. Gharib, A. D. Irwin, E. Wijsman, T. Vaisar, J. F. Oram, and J. W. Heinecke. 2010. A macrophage sterol-responsive network linked to atherogenesis. Cell Metab. 11: 125-135.
43. Silva, J. C., M. V. Gorenstein, G-z. Li, J. P. C. Vissers, and S. J. Geromanos. 2006. Absolute quantification of proteins by LCMSE: a virtue of parallel MS acquisition. Molecular & cellular proteomics. 5: 144-156.
44. Hutchins, P. M., G. E. Ronsein, J. S. Monette, N. Pamir, J. Wimberger, Y. He, G. M. Anantharamaiah, D. S. Kim, J. E. Ranchalis, G. P. Jarvik, et al. 2014. Quantification of HDL particle concentration by calibrated ion mobility analysis. Clin. Chem. 60: 1393-1401.
45. Davidson, W. S. 2014. HDL Proteome Watch. Accessed January 30, 2015, at http://homepages.uc.edu/~davidswm/HDLproteome. html.
46. Alaupovic, P. 1996. Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins. Methods Enzymol. 263: 32-60.
47. Hoofnagle, A. N., and J. W. Heinecke. 2009. Lipoproteomics: using mass spectrometry-based proteomics to explore the assembly, structure, and function of lipoproteins. J. Lipid Res. 50: 1967-1975.
48. Cheung, M. C., and J. J. Albers. 1984. Characterization of lipoprotein particles isolated by immunoaffinity chromatography. Particles containing A-I and A-II and particles containing A-I but no A-II. J. Biol. Chem. 259: 12201-12209.
49. Khovidhunkit, W., M. S. Kim, R. A. Memon, J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld. 2004. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 45: 1169-1196.
50. Watanabe, J., V. Grijalva, S. Hama, K. Barbour, F. Berger, M. Navab, A. M. Fogelman, and S. T. Reddy. 2009. Hemoglobin and its scavenger protein haptoglobin associate with apoA-1 containing particles and influence the inflammatory properties and function of high density lipoprotein. J. Biol. Chem. 284: 18292-18301.
51. Shao, B., C. Tang, J. W. Heinecke, and J. F. Oram. 2010. Oxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol export. J. Lipid Res. 51: 1849-1858.
52. Shao, B., G. Cavigiolio, N. Brot, M. N. Oda, and J. W. Heinecke. 2008. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc. Natl. Acad. Sci. USA. 105: 12224-12229.
53. Shao, B., M. N. Oda, C. Bergt, X. Fu, P. S. Green, N. Brot, J. F. Oram, and J. W. Heinecke. 2006. Myeloperoxidase impairs ABCA1- dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I. J. Biol. Chem. 281: 9001-9004.
54. Huang, Y., J. A. DiDonato, B. S. Levison, D. Schmitt, L. Li, Y. Wu, J. Buffa, T. Kim, G. S. Gerstenecker, X. Gu, et al. 2014. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat. Med. 20: 193-203.
55. de Beer, M. C., A. Ji, A. Jahangiri, A. M. Vaughan, F. C. de Beer, D. R. van der Westhuyzen, and N. R. Webb. 2011. ATP binding cassette G1-dependent cholesterol efflux during inflammation. J. Lipid Res. 52: 345-353.
56. Davidson, W. S., K. L. Gillotte, S. Lund-Katz, W. J. Johnson, G. H. Rothblat, and M. C. Phillips. 1995. The effect of high density lipoprotein phospholipid acyl chain composition on the efflux of cellular free cholesterol. J. Biol. Chem. 270: 5882-5890.
57. Camont, L., M. Lhomme, F. Rached, W. Le Goff, A. Nègre- Salvayre, R. Salvayre, C. Calzada, M. Lagarde, M. J. Chapman, and A. Kontush. 2013. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, antiinflammatory, and antiapoptotic functionalities. Arterioscler. Thromb. Vasc. Biol. 33: 2715-2723.
58. de Beer, F. C., M. C. de Beer, D. R. van der Westhuyzen, L. W. Castellani, A. J. Lusis, M. E. Swanson, and D. S. Grass. 1997. Secretory non-pancreatic phospholipase A2: influence on lipoprotein metabolism. J. Lipid Res. 38: 2232-2239.
59. Libby, P. 2002. Inflammation in atherosclerosis. Nature. 420: 868-874.
60. Pruzanski, W., E. Stefanski, F. C. de Beer, M. C. de Beer, A. Ravandi, and A. Kuksis. 2000. Comparative analysis of lipid composition of normal and acute-phase high density lipoproteins. J. Lipid Res. 41: 1035-1047.
61. Hudgins, L. C., T. S. Parker, D. M. Levine, B. R. Gordon, S. D. Saal, X. C. Jiang, C. E. Seidman, J. D. Tremaroli, J. Lai, and A. L. Rubin. 2003. A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers. J. Lipid Res. 44: 1489-1498.
62. Shao, B., S. Pennathur, I. Pagani, M. N. Oda, J. L. Witztum, J. F. Oram, and J. W. Heinecke. 2010. Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol efflux by the ABCA1 pathway. J. Biol. Chem. 285: 18473-18484.
63. Tam, S. P., A. Flexman, J. Hulme, and R. Kisilevsky. 2002. Promoting export of macrophage cholesterol: the physiological role of a major acute-phase protein, serum amyloid A 2.1. J. Lipid Res. 43: 1410-1420.
64. Husebekk, A., B. Skogen, and G. Husby. 1987. Characterization of amyloid proteins AA and SAA as apolipoproteins of high density lipoprotein (HDL). Displacement of SAA from the HDL-SAA complex by apo AI and apo AII. Scand. J. Immunol. 25: 375-381.
65. Cabana, V. G., C. A. Reardon, B. Wei, J. R. Lukens, and G. S. Getz. 1999. SAA-only HDL formed during the acute phase response in apoA-I+/+ and apoA-I - / - mice. J. Lipid Res. 40: 1090-1103.
66. de Beer, M. C., J. M. Wroblewski, V. P. Noffsinger, A. Ji, J. M. Meyer, D. R. V. D. Westhuyzen, F. C. de Beer, and N. R. Webb. 2013. The impairment of macrophage-to-feces reverse cholesterol transport during inflammation does not depend on serum amyloid A. J. Lipids. 2013: 283486.
67. Tsun, J. G., S. W. Shiu, Y. Wong, S. Yung, T. M. Chan, and K. C. Tan. 2013. Impact of serum amyloid A on cellular cholesterol efflux to serum in type 2 diabetes mellitus. Atherosclerosis. 231: 405-410.
68. Adorni, M. P., F. Zimetti, J. T. Billheimer, N. Wang, D. J. Rader, M. C. Phillips, and G. H. Rothblat. 2007. The roles of different pathways in the release of cholesterol from macrophages. J. Lipid Res. 48: 2453-2462.
69. Sankaranarayanan, S., J. F. Oram, B. F. Asztalos, A. M. Vaughan, S. Lund-Katz, M. Adorni, M. C. Phillips, and G. H. Rothblat. 2009. Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux. J. Lipid Res. 50: 275-284.
70. Hosoai, H., N. R. Webb, J. M. Glick, U. J. Tietge, M. S. Purdom, F. C. de Beer, and D. J. Rader. 1999. Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL cholesterol or apoA-I levels in human apoA-I transgenic mice. J. Lipid Res. 40: 648-653.
71. de la Llera Moya, M., F. C. McGillicuddy, C. C. Hinkle, M. Byrne, M. R. Joshi, V. Nguyen, J. Tabita-Martinez, M. L. Wolfe, K. Badellino, L. Pruscino, et al. 2012. Inflammation modulates human HDL composition and function in vivo. Atherosclerosis. 222: 390-394.
72. De Beer, M. C., J. M. Wroblewski, V. P. Noffsinger, D. L. Rateri, D. A. Howatt, A. Balakrishnan, A. Ji, P. Shridas, J. C. Thompson, D. R. van der Westhuyzen, et al. 2014. Deficiency of endogenous acute phase serum amyloid A does not affect atherosclerotic lesions in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 34: 255-261.
73. Dong, Z., T. Wu, W. Qin, C. An, Z. Wang, M. Zhang, Y. Zhang, C. Zhang, and F. An. 2011. Serum amyloid A directly accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Mol. Med. 17: 1357-1364.
74. Thompson, J. C., C. Jayne, J. Thompson, P. G. Wilson, M. H. Yoder, N. Webb, and L. R. Tannock. 2015. A brief elevation of serum amyloid A is sufficient to increase atherosclerosis. J. Lipid Res. 56: 286-293.
75. Subramanian, S., C. Y. Han, T. Chiba, T. S. McMillen, S. A. Wang, A. Haw, E. A. Kirk, K. D. O'Brien, and A. Chait. 2008. Dietary cholesterol worsens adipose tissue macrophage accumulation and atherosclerosis in obese LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 28: 685-691.
76. Vivekanandan-Giri, A., J. L. Slocum, J. Byun, C. Tang, R. L. Sands, B. W. Gillespie, J. W. Heinecke, R. Saran, M. J. Kaplan, and S. Pennathur. 2013. High density lipoprotein is targeted for oxidation by myeloperoxidase in rheumatoid arthritis. Ann. Rheum. Dis. 72: 1725-1731.
77. Hafiane, A., B. Jabor, I. Ruel, J. Ling, and J. Genest. 2014. Highdensity lipoprotein mediated cellular cholesterol efflux in acute coronary syndromes. Am. J. Cardiol. 113: 249-255.
78. Zabalawi, M., M. Bharadwaj, H. Horton, M. Cline, M. Willingham, M. J. Thomas, and M. G. Sorci-Thomas. 2007. Inflammation and skin cholesterol in LDLr-/-, apoA-I-/- mice: link between cholesterol homeostasis and self-tolerance? J. Lipid Res. 48: 52-65.
79. Ridker, P. M., N. Rifai, M. A. Pfeffer, F. M. Sacks, L. A. Moye, S. Goldman, G. C. Flaker, and E. Braunwald. 1998. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 98: 839-844.
80. Danesh, J., P. Whincup, M. Walker, L. Lennon, A. Thomson, P. Appleby, J. R. Gallimore, and M. B. Pepys. 2000. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 321: 199-204.